Charles River Laboratories (CRL)

• Market cap: $8.34B
• 1 day: 0.47%
• 5 days: 5.16%
• 1 month: -4.00%
• 3 months: -16.05%
• 6 months: -20.24%
• Year to date: -10.74%
• 1 year: -32.38%
• 5 years: -6.12%
• 10 years: 112.49%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

13% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 82

2.05% more ownership

Funds ownership: 101.36% [Q3] → 103.41% (+2.05%) [Q4]

4% less capital invested

Capital invested by funds: $10.3B [Q3] → $9.88B (-$381M) [Q4]

2% less funds holding

Funds holding: 618 [Q3] → 607 (-11) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

37% less repeat investments, than reductions

Existing positions increased: 172 | Existing positions reduced: 271

42% less call options, than puts

Call options by funds: $28.5M | Put options by funds: $49.3M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $160 2% downside
• Avg. target: $181 11% upside
• High target: $210 29% upside

7 analyst ratings

• positive: 1 14%
• neutral: 6 86%
• negative: 0 0%

JP Morgan Casey Woodring 0% 1-year accuracy 0 / 6 met price target	1% upside $165	Neutral Maintained	20 Feb 2025
Baird Eric Coldwell 42% 1-year accuracy 13 / 31 met price target	6% upside $173	Neutral Maintained	20 Feb 2025
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	2% downside $160	Equal-Weight Maintained	20 Feb 2025
Morgan Stanley Ricky Goldwasser 50% 1-year accuracy 8 / 16 met price target	13% upside $184	Equal-Weight Maintained	5 Feb 2025
Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	17% upside $190	Buy Maintained	23 Jan 2025